Exploratory study of chemotherapy combined with endocrine therapy for metastatic breast cancer after standard treatment failure
10.3760/cma.j.issn.1006-9801.2013.07.004
- VernacularTitle:化疗联合内分泌治疗对标准治疗失败晚期转移性乳腺癌的探索性研究
- Author:
Tingting YANG
;
Tao WANG
;
Li BIAN
;
Huiqiang ZHANG
;
Shaohua ZHANG
;
Shikai WU
;
Zefei JIANG
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Neoplasm metastasis;
Drug therapy;
Standard treatment failure;
Endocrine therapy
- From:
Cancer Research and Clinic
2013;25(7):445-447
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical value of chemotherapy combined with endocine therapy after standard treatment failure for advanced metastatic breast cancer.Methods 30 metastatic breast cancer patients after standard treatment failure were analyzed.Etoposide (75-100 mg/d) wasused on days 1-10,followed by 11 days of rest combined with medroxyprogesterone 0.5 g,twice per day,or megestrol 160 mg/d for 21 days.Clinical effects and life quility were analysed.Results The median treatment line of this therapy was 6 (range 3-9).The clinical benefit rate is 16.7 ％ (5/30),and the median progression free survival (PFS) was 4.0 months (range 1.0-13.0 months).Conclusion The combination of chemotherapy (etoposide) and endocrine therapy (progesterone) is a choice of treatment after standard drug failure for advanced mastatic breast cancer patients.
